1. Scrip

Double Dose: After Stelis, Strides Readies SteriScience For Injectables Push

New JVs For Carbapenems With Brooks Labs

 
• By Vibha Ravi

Strides is expanding its presence in synthetic injectables via a new company, SteriScience, while keeping its biologics injectables business under Stelis. A head start with existing IP assets and those from a new joint venture with Brooks Labs will enable the fledgling firm to file its first ANDA in fiscal 2021, with break-even seen in two years.

World environment day concept: Two human hands holding big and small trees on blurred farming background
With Stelis Set For Growth, Strides Forms New Company • Source: Shutterstock

India's Strides Pharma Science Limited is expanding its injectables portfolio through a new company, SteriScience Pharma Pvt. Ltd., which will only develop and market synthetic injectables, while manufacturing will be undertaken at third party sites, including at facilities owned by Stelis BioPharma Pvt. Ltd.

Strides will have a 54% stake in SteriScience, with the remaining 46% to be held by Strides’ promoter group led...

More from India

More from Focus On Asia